What parents need to know about mosquito disease vaccines for children in 2026. Age restrictions for Qdenga (4+), VIMKUNYA (12+), and why physical protection is essential for young children.
Mosquito Disease Vaccines for Children: What Parents Should Know
As mosquito-borne diseases spread into new regions, and as families keep travelling to the tropics with children, parents are asking what vaccines can protect their child. The answer in 2026 is better than a few years ago, but it comes with age limits every parent needs to understand.
The Current Vaccine Landscape for Children
Qdenga (Dengue): Ages 4 and Older
Qdenga is the most widely available dengue vaccine for children, approved in the EU and 41+ countries for individuals aged four years and older. The age cutoff at four leaves the youngest, often most vulnerable, children without dengue vaccine protection.
What parents should know about Qdenga for children:
- The vaccine requires two doses given three months apart, so plan well ahead of any travel
- No prior dengue testing is needed -- unlike Dengvaxia, Qdenga can be given regardless of whether your child has had dengue before
- Side effects in children are largely consistent with adults, though certain reactions occur more frequently in younger age groups:
- Fever: 11% in children versus 3% in adults
- Upper respiratory tract infection: 11% versus 3%
- In children under 6 who received the vaccine: decreased appetite (17%), sleepiness (13%), and irritability (12%)
- Side effects are mild to moderate and typically resolve within a few days
- The vaccine is contraindicated in children with weakened immune systems
VIMKUNYA (Chikungunya): Ages 12 and Older
VIMKUNYA is the only chikungunya vaccine available following the FDA suspension of IXCHIQ. However, it is only approved for individuals aged 12 and older. IXCHIQ was only approved for adults 18+, so VIMKUNYA actually represents an improvement in paediatric coverage -- but children under 12 still have no chikungunya vaccine option.
Yellow Fever: Ages 9 Months and Older (Generally)
The yellow fever vaccine is generally recommended for children aged nine months and older travelling to endemic areas. It may be given to infants as young as six months in certain high-risk circumstances, but this requires careful medical assessment. This is a live attenuated vaccine and carries rare risks of serious adverse events.
Japanese Encephalitis (IXIARO): Ages 2 Months and Older
IXIARO can be administered to children as young as two months of age when travelling to JE-endemic areas, making it one of the most accessible mosquito disease vaccines for young children. The dosing schedule for children under three differs from the adult schedule.
Malaria Vaccines: For Children in Endemic Africa Only
Both RTS,S (Mosquirix) and R21/Matrix-M are WHO-recommended for children in malaria-endemic regions, typically starting at 5-6 months of age. These vaccines are not available for travellers' children in non-endemic countries. Children travelling to malaria-endemic areas need antimalarial prophylaxis rather than vaccination.
The Critical Gaps: Who Is Left Unprotected
Infants and Toddlers (Under 4): No Dengue Vaccine
The under-four age group cannot receive Qdenga. Safety and efficacy data in this age group are not yet sufficient to support approval. Clinical trials for this population are complex, and regulators hold paediatric approvals to high standards.
This gap matters because young children are among the most vulnerable to severe dengue. Their developing immune systems can mount exaggerated inflammatory responses, and they are less able to communicate symptoms that might indicate deterioration.
Children Ages 4-11: No Chikungunya Vaccine
Children in this age range can receive Qdenga for dengue but have no chikungunya vaccine option. With chikungunya expanding in Europe and remaining endemic in Asia, the Caribbean, and Africa, this represents a meaningful protection gap.
No Vaccine for West Nile or Zika at Any Age
There is no licensed vaccine for West Nile virus or Zika for any age group. Children in southern Europe, where West Nile virus circulates seasonally, and pregnant women concerned about Zika have no vaccine-based protection options.
Age Restriction Summary Table
| Vaccine | Disease | Minimum Age | Notes |
|---|---|---|---|
| Qdenga | Dengue | 4 years | Two doses, 3 months apart |
| VIMKUNYA | Chikungunya | 12 years | VLP vaccine, cannot cause infection |
| Yellow Fever | Yellow fever | 9 months (6 months in emergencies) | Required for travel to many countries |
| IXIARO | Japanese encephalitis | 2 months | Two-dose series |
| R21/Matrix-M | Malaria | ~5 months | Only in endemic Africa programs |
| None available | West Nile virus | N/A | No vaccine at any age |
| None available | Zika | N/A | No vaccine at any age |
Why Physical Protection Is Non-Negotiable for Young Children
Given the vaccine gaps, physical bite prevention is the primary line of defence for children, especially those too young to be vaccinated.
Strategies for Protecting Infants and Young Children
For infants under 2 months (when no repellents are recommended):
- Use mosquito nets over strollers, carriers, and cribs
- Dress the baby in loose, light-coloured long sleeves and trousers
- Stay in screened or air-conditioned environments during peak mosquito hours
- Ensure all windows and doors have intact screens
For children 2 months and older:
- Apply age-appropriate insect repellent to exposed skin (DEET up to 30% is safe for children over 2 months, as is picaridin and IR3535)
- Apply repellent to your own hands first, then apply to the child's skin -- avoid hands, eyes, and mouth
- Use permethrin-treated clothing for older children, especially in highly endemic areas
- Continue to use bed nets and screened environments
For all children:
- Eliminate standing water around your home and accommodation
- Be especially vigilant at dusk and dawn (for Culex-borne diseases like West Nile) and during daytime (for Aedes-borne diseases like dengue and chikungunya)
- When travelling, choose accommodations with functioning screens or air conditioning
- Carry a portable bed net for destinations where screening may be unreliable
Repellent Safety for Children
The evidence supports the safety of DEET-based repellents for children when used as directed:
- DEET concentrations up to 30% are appropriate for children over 2 months
- Picaridin (20%) is an effective and well-tolerated alternative
- Oil of lemon eucalyptus should not be used on children under 3 years
- Do not apply repellent to cuts, wounds, or irritated skin
- Wash treated skin with soap and water when returning indoors
When to Consult a Paediatric Travel Medicine Specialist
If you are planning travel with children to mosquito-endemic destinations, consult a travel medicine provider at least three to six months in advance. This allows time to:
- Complete multi-dose vaccine schedules (Qdenga needs three months)
- Assess your child's specific risk based on destination, duration, and season
- Determine appropriate antimalarial prophylaxis if needed
- Plan physical protection strategies tailored to your child's age
What Parents Should Do
The mosquito disease vaccine toolkit for children is growing but incomplete. Qdenga from age four and VIMKUNYA from age twelve are genuine advances. But until vaccines exist for every mosquito-borne disease at every age, physical protection against bites remains the foundation of keeping children safe.
This is especially true for the youngest children, infants and toddlers under four, who have access to the fewest vaccines and face some of the highest risks. For them, the bed net, the repellent, the screened window, and the long-sleeved shirt are the primary defence, not supplements to vaccination.
Sources
This article is general information, not medical advice. Ask a doctor or pharmacist about your own health.